Latest News and Press Releases

First to demonstrate single dose, in vivo results, showing approximately 97 percent reduction in serum transthyretin protein levelsFurther established a comprehensive platform, including a proprietary...

First to demonstrate single dose, in vivo results, showing approximately a 97 percent reduction in serum transthyretin protein levels Durability data show stable liver editing for at least four...

CAMBRIDGE, Mass., March 01, 2017 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading genome editing company focused on the development of potentially curative therapeutics using...

CAMBRIDGE, Mass., Feb. 15, 2017 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (Nasdaq:NTLA) will hold a conference call with investors on Thursday, February 16, 2017 at 8 a.m.,...

UC’s patent application covering the use of CRISPR/Cas9 genome editing technology with a single-guide RNA format in any non-cellular or cellular setting, including human and other eukaryotic cells,...

CAMBRIDGE, Mass., Feb. 01, 2017 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading genome editing company focused on the development of potentially curative therapeutics...

CAMBRIDGE, Mass. and LONDON, Jan. 11, 2017 (GLOBE NEWSWIRE) -- Intellia Therapeutics (NASDAQ:NTLA) has joined the Genomics England Genomics Expert Network for Enterprises (GENE) Consortium, as the...

CAMBRIDGE, Mass., Dec. 13, 2016 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading genome editing company focused on developing potentially curative therapeutics using...

- Positions Intellia for R&D growth and progress toward clinical studies -- Accommodates hiring plans to support pipeline of CRISPR/Cas9 based therapeutics - CAMBRIDGE, Mass., Dec. 01, 2016 ...

First company to report high in vivo editing data using CRISPR/Cas9 in animal modelsFurther validation of lipid nanoparticle delivery platformEnded quarter with $290.6 million in cash and cash...